loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Darovasertib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Darovasertib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    IDEAYA Biosciences Reports Q2 2024 Results And Business Update
    IDEAYA Biosciences Reports Q2 2024 Results And Business Update

    06 Aug 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-inc-reports-second-quarter-2024-financial-results-and-provides-business-update-302214993.html

    PR NEWSWIRE
    06 Aug 2024
    Share Share
    Ideaya announces results for darovasertib ph 2 IST in neoadjuvant uveal at ASCO
    Ideaya announces results for darovasertib ph 2 IST in neoadjuvant uveal at ASCO

    05 Jun 2024

    // PHARMABIZ

    https://www.pharmabiz.com/NewsDetails.aspx?aid=169554&sid=2

    PHARMABIZ
    05 Jun 2024
    Share Share
    IDEAYA's Darovasertib Uveal Melanoma, Neoadjuvant Data At ASCO
    IDEAYA's Darovasertib Uveal Melanoma, Neoadjuvant Data At ASCO

    03 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-announces-results-for-darovasertib-phase-2-ist-in-neoadjuvant-uveal-melanoma-at-asco-and-clinical-update-for-phase-2-company-sponsored-neoadjuvant-study-302161137.html

    PR NEWSWIRE
    03 Jun 2024
    Share Share
    Ideaya Darovasertib Uveal Summary: Ph2 Neoadjuvant Asco Oral Presentation
    Ideaya Darovasertib Uveal Summary: Ph2 Neoadjuvant Asco Oral Presentation

    23 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-abstract-summary-results-of-asco-2024-oral-presentation-for-phase-2-investigator-sponsored-study-of-darovasertib-in-neoadjuvant-uveal-melanoma-302154551.html

    PR NEWSWIRE
    23 May 2024
    Share Share
    IDEAYA's Darovasertib Uveal Melanoma Data in ASCO Oral Session
    IDEAYA's Darovasertib Uveal Melanoma Data in ASCO Oral Session

    24 Apr 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-asco-2024-oral-presentation-for-darovasertib-in-neoadjuvant-uveal-melanoma-phase-2-investigator-sponsored-study-302125242.html

    PR NEWSWIRE
    24 Apr 2024
    Share Share
    IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023
    IDEAYA Biosciences Announces Proffered Paper Oral Presentation at ESMO 2023

    17 Oct 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-proffered-paper-oral-presentation-at-esmo-2023-for-phase-2-clinical-data-update-for-darovasertib-and-crizotinib-combination-in-metastatic-uveal-melanoma-301958315.html

    PR NEWSWIRE
    17 Oct 2023
    Share Share